Abstract
New research on Surgery - Nephrectomy is the subject of a report. According to news reporting from Beijing, People’s Republic of China, by NewsRx journalists, research stated, “AirSeal is a valve-less trocar insufflation system which is widely used in robotic urologic surgeries. More evidence is needed concerning the application and cost of AirSeal in retroperitoneal robot-assisted laparoscopic partial nephrectomy.” The news correspondents obtained a quote from the research from Peking Union Medical College Hospital, “We conducted a randomized controlled trial enrolling 62 patients who underwent retroperitoneal robot-assisted laparoscopic partial nephrectomy from February 2022 to February 2023 in the Peking Union Medical College Hospital. Patients were randomly assigned into AirSeal insufflation (AIS) group and conventional insufflation (CIS) group. The primary outcome was the rate of subcutaneous emphysema (SCE). The SCE rate in the AIS group (12.9%) was significantly lower than that in the CIS group (35.5%) (P = 0.038). Lower maximum end-tidal carbon dioxide (CO) (41 vs 45 mmHg, P = 0.011), PaCO at the end of the operation (40 vs 45 mmHg, P<0.001), maximum tidal volume (512 vs 570 ml, P = 0.003), frequency of lens cleaning (3 vs 5, P<0.001), pain score at 8 h (3 vs 4, P = 0.025), 12 h (2 vs 3, P = 0.029) postoperatively and at time of discharge (1 vs 2, P = 0.002) were observed in the AIS group, despite a higher hospitalization cost (68,197 vs 64658RMB, P<0.001). Logistic regression analysis identified insufflation approach was the only influencing factor for the occurrence of SCE events.”
NETL
NSTL
Springer Nature